期刊
FREE RADICAL BIOLOGY AND MEDICINE
卷 157, 期 -, 页码 15-37出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.freeradbiomed.2020.02.026
关键词
Cardiovascular disease; Endothelial dysfunction; Oxidative stress; Redox drugs
资金
- Boehringer Ingelheim Foundation
- FNP TEAM [POIR.04.04.00-00-5CAC/17-00]
- SYMFONIA NCN [DEC-2015/16/W/NZ4/00070]
- OPUS NCN [2018/29/B/NZ7/01684]
- European COST Action EU-CARDIOPROTECTION [CA16225]
- [STRATEGMED1/233226/11/NCBR/2015]
According to the latest Global Burden of Disease Study data, non-communicable diseases in general and cardiovascular disease (CVD) in particular are the leading cause of premature death and reduced quality of life. Demographic shifts, unhealthy lifestyles and a higher burden of adverse environmental factors provide an explanation for these findings. The expected growing prevalence of CVD requires enhanced research efforts for identification and characterisation of novel therapeutic targets and strategies. Cardiovascular risk factors including classical (e.g. hypertension, diabetes, hypercholesterolaemia) and non-classical (e.g. environmental stress) factors induce the development of endothelial dysfunction, which is closely associated with oxidant stress and vascular inflammation and results in CVD, particularly in older adults. Most classically successful therapies for CVD display vasoprotective, antioxidant and anti-inflammatory effects, but were originally designed with other therapeutic aims. So far, only a few 'redox drugs' are in clinical use and many antioxidant strategies have not met expectations. With the present review, we summarise the actual knowledge on CVD pathomechanisms, with special emphasis on endothelial dysfunction, adverse redox signalling and oxidative stress, highlighting the preclinical and clinical evidence. In addition, we provide a brief overview of established CVD therapies and their relation to endothelial dysfunction and oxidative stress. Finally, we discuss novel strategies for redox-based CVD therapies trying to explain why, despite a clear link between endothelial dysfunction and adverse redox signalling and oxidative stress, redox-and oxidative stress-based therapies have not yet provided a breakthrough in the treatment of endothelial dysfunction and CVD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据